Clinical Trial Update: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial of crenolanib, a PDGFR inhibitor, in pediatric patients with Diffuse Intrinsic Pontine Glioma or recurrent high-grade glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• High-grade Glioma

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Diffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma | Phase 1 | Status: COMPLETED